Report Library

All Reports
Renal Cell Carcinoma (RCC) KOL Interview - UK

May 07, 2024

Interview addressing the transformation surrounding RCC with new systemic therapies and the changing approaches to surgery in combination with adjuvant therapy. The importance of trying to maximize outcomes to reduce patient discontinuation when using first-line regimens is also discussed, as well as trial failures and the potential reasons behind them. 

This interview was conducted on 12 April 2024. 

If you are a KOL Insight Subscriber, you may also access the interview from our KOL Insight portal

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.

Indications Covered: Renal Cell Cancer (RCC)

 Additional Resources: